# SCIENTIFIC REPORTS

Received: 16 December 2015 Accepted: 14 March 2016 Published: 07 April 2016

## **OPEN** Allosteric Partial Inhibition of **Monomeric Proteases. Sulfated Coumarins Induce Regulation, not** just Inhibition, of Thrombin

Stephen Verespy III<sup>1,2</sup>, Akul Y. Mehta<sup>1,3</sup>, Daniel Afosah<sup>1,3</sup>, Rami A. Al-Horani<sup>1,3</sup> & Umesh R. Desai<sup>1,3</sup>

Allosteric partial inhibition of soluble, monomeric proteases can offer major regulatory advantages, but remains a concept on paper to date; although it has been routinely documented for receptors and oligomeric proteins. Thrombin, a key protease of the coagulation cascade, displays significant conformational plasticity, which presents an attractive opportunity to discover small molecule probes that induce sub-maximal allosteric inhibition. We synthesized a focused library of some 36 sulfated coumarins to discover two agents that display sub-maximal efficacy ( $\sim$ 50%), high potency (<500 nM) and high selectivity for thrombin (>150-fold). Michaelis-Menten, competitive inhibition, and sitedirected mutagenesis studies identified exosite 2 as the site of binding for the most potent sulfated coumarin. Stern-Volmer guenching of active site-labeled fluorophore suggested that the allosteric regulators induce intermediate structural changes in the active site as compared to those that display ~80–100% efficacy. Antithrombin inactivation of thrombin was impaired in the presence of the sulfated coumarins suggesting that allosteric partial inhibition arises from catalytic dysfunction of the active site. Overall, sulfated coumarins represent first-in-class, sub-maximal inhibitors of thrombin. The probes establish the concept of allosteric partial inhibition of soluble, monomeric proteins. This concept may lead to a new class of anticoagulants that are completely devoid of bleeding.

Allosterism induced by small or large molecule effectors is increasingly being perceived as a new paradigm to understand molecular pathways and discover new therapeutics<sup>1,2</sup>. It refers to modulating a protein's biological function through allosteric (distal) sites, rather than it's orthosteric (active) site. Small molecules that target allosteric sites have become extremely useful probes for advancing chemical biology and drug discovery projects<sup>1-3</sup>. A range of allosteric targets are described in the literature including receptors or membrane-bound proteins<sup>3-6</sup>, kinases<sup>7,8</sup>, and proteases<sup>1,9-12</sup>.

Intrinsically, allostery offers some major advantages over orthostery. Whereas orthosteric sites between related proteins/enzymes are similar, e.g., trypsin-like serine proteases<sup>10,13</sup>, allosteric sites are typically less conserved<sup>1,5,14</sup>. Allostery can afford dramatic changes in the type of biological function, e.g., procoagulation to anticoagulation, while orthostery can afford only a reduction in biological activity, e.g., inhibition of catalytic activity. Finally, allostery presents two parameters – potency ( $IC_{50}$ ) and efficacy ( $\% \Delta Y$ ) – for regulation of activity, whereas orthostery presents only one, i.e., potency, for regulation (Fig. 1)<sup>15</sup>. More specifically, allosteric induction of function depends on the cooperativity between the distal and active sites, which is expected to be sensitive to the structure of the allosteric ligand, and thereby, may exhibit variable levels of cooperativity. Alternatively, whereas one allosteric ligand may exhibit maximum possible conformational change in the active site at saturation  $(\Delta Y = 80-100\%)$ , another may exhibit only partial conformational change at saturation ( $\Delta Y = 30-70\%$ ). Such a phenomenon is not possible for orthosteric ligands and thus, allostery offers better regulation possibilities. Yet, partial or sub-maximal allosteric regulators, more often described as partial agonists or antagonists of receptors<sup>16</sup>,

<sup>1</sup>Institute for Structural Biology, Drug Discovery and Development, Virginia Commonwealth University, Richmond, Virginia, USA. <sup>2</sup>Department of Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA. <sup>3</sup>Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, Virginia, USA. Correspondence and requests for materials should be addressed to U.R.D. (email: urdesai@vcu.edu)



**Figure 1.** Allosterism and inhibition. (A) Allostery offers several major advantages over orthostery. Whereas both allostery and orthostery offer potency ( $IC_{50}$ ) for regulating inhibition, allostery (especially partial allostery) offers efficacy (%  $\Delta$ Y) in addition for controlling protease inhibition. (B) Thrombin, a soluble monomeric protease, is a highly plastic enzyme that displays multiple conformational isoforms in its ground state<sup>19,21,57</sup>. These conformational forms, labeled 1 through 4, are in equilibrium, which can theoretically be enriched through small molecules that bind at an allosteric site. Such allosteric agents may display partial inhibition of the protease at saturation, a phenomenon not known for monomeric proteases.

.....

have been extensively described for receptors/membrane-bound proteins<sup>16,17</sup> and oligomeric, secreted proteins<sup>18</sup>, but remain unknown for soluble, monomeric proteins, e.g., proteases.

A key protease of special interest to the field of blood coagulation is thrombin. Thrombin is a trypsin-like monomeric protease that functions as a procoagulant by cleaving soluble fibrinogen into fibrin and as an anticoagulant by activating protein C in the presence of thrombomodulin<sup>19,20</sup>. In addition, thrombin recognizes multiple natural substrates, e.g., factors V, VIII, XI and others, and unnatural agents, e.g., hirudin. Thrombin exhibits considerable structural plasticity by sampling a number of conformational forms in its ground state<sup>19–21</sup>, which are in equilibrium with each other (Fig. 1). Theoretically, this equilibrium can be perturbed by appropriate small molecules/ions. In fact, Na<sup>+</sup> ion is recognized as a natural modulator of thrombin activity. Na<sup>+</sup> binding to thrombin enhances substrate hydrolysis, whereas absence of Na<sup>+</sup> shifts the equilibrium to a "slow" form<sup>22</sup>.

We reasoned that thrombin is an ideal monomeric protease for discovering small molecule probes that display sub-maximal conformational change at saturation. Such probes would induce only a 50% cleavage of substrates at saturation ( $\Delta Y = ~30-70\%$ ) and afford the possibility of better regulation of the protease. For example, current orthosteric inhibitors of thrombin (dabigatran, argatroban, etc.) inhibit thrombin with maximal efficacy ( $\Delta Y = 100\%$ ), which contributes to enhanced risk of bleeding<sup>23,24</sup>. In contrast, we predict that sub-maximal inhibitors of thrombin will retain some hemostatic potential, which will prevent bleeding consequences<sup>25</sup>. However, such small molecule sub-maximal allosteric regulators of thrombin remain unknown.

We have earlier studied a number of sulfated non-saccharide glycosaminoglycan allosteric modulators (NSGMs) of thrombin including sulfated benzofurans<sup>26–29</sup> and sulfated low molecular weight lignins<sup>30,31</sup>. These NSGMs display inhibition efficacy in the range of 70–100% and are more accurately "inhibitors" rather than "regulators". In this work, we present sulfated coumarins as novel allosteric regulators of thrombin with excellent potency and high selectivity for thrombin. Kinetic and thermodynamic studies suggest that inhibition arises from a sub-maximal change in the conformation/structure of the active site. Thus, sulfated coumarins represent first-in-class, allosteric regulators of thrombin and establish the idea that it is possible to realize sub-maximal allosteric regulators of soluble, monomeric proteins.



Figure 2. Structures of sulfated coumarins synthesized in this study to discover partial allosteric inhibitors of thrombin. 1a–d are monomeric agents composed of only the coumarin core; 2a–y are monomeric sulfated coumarins with 3-phenyl substitution; 3a–f are dimeric "head-to-head" agents; and 3g is the dimeric "head-to-tail" sulfated coumarin. Note: When a particular substituent  $\mathbf{R}_i = \mathbf{H}$ , it is not listed in above descriptions.

### Results & Discussion

**Synthesis of a Library of Sulfated Coumarins.** In our quest to discover allosteric partial regulators, especially of thrombin, we decided to study the sulfated coumarin scaffold. Our earlier work on designing/discovering allosteric modulators of thrombin led to the sulfated quinazolinone and benzofuran scaffolds, which exhibited allosterism, but induced full inhibition ( $\Delta Y = 80-100\%$ ) at saturation<sup>26–29</sup>. Although sulfated coumarins are similar to sulfated quinazolinones and sulfated benzofurans studied earlier in carrying one or more sulfate groups, the aromatic scaffold is fundamentally different. The unique electrotopological nature<sup>31</sup> of coumarins coupled with their synthetic accessibility<sup>32</sup> led us to investigate whether this scaffold can provide allosteric partial regulator(s) of thrombin.

Sulfated coumarins were synthesized using either a protection–deprotection strategy or a selective reaction strategy, which enabled the generation of the desired number of free phenolic/alcoholic groups that can be sulfated in the final step using sulfur trioxide–trialkylamine complex<sup>27–29,33</sup>. One advantage here was that quite a few naturally occurring coumarins were available, which could be directly sulfated under microwave-assisted conditions, as described previously<sup>34,35</sup>. This led to the synthesis of monomeric sulfated coumarins **1a–1d** and **2a–2v** (Fig. 2) in high yields (82–99%) and high purity (>95%, see Supplementary Fig. S1). Likewise, naturally occurring *O*-methylated coumarins were deprotected utilizing BBr<sub>3</sub> and then sulfated to synthesize **2x–2z** in yields of 91–94% (Fig. 2 and Supplementary Fig. S2).

To synthesize dimeric analogs of sulfated coumarins, a copper-assisted azide-alkyne cycloaddition (CuAAC) was employed, in which selective  $S_N^2$ -based coupling at the most reactive phenol (7-OH group) led to synthesis of head-to-head dimers **3a**–**3f** in yields of 72–90% (Fig. 2 and Supplementary Fig. S3). The structures of these agents were confirmed through detailed 2D NMR experiments that unambiguously established the position of reaction under these conditions (see Supplementary Figs S4 and S5). Likewise, the head-to-tail dimer **3g** and **3h** was also synthesized utilizing the conditions developed for the head-to-head dimers with appropriate modifications in excellent yields (Fig. 2). The head-to-tail structure of **3g** was also confirmed through 2D NMR (Supplementary



**Figure 3. Sulfated coumarins as inhibitors of thrombin.** (A) Dose-response profiles of selected sulfated coumarins (and non-sulfated **3g**) against thrombin in 20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% PEG 8000, pH 7.4 at 25 °C. (B) Spectrofluorometric measurement of the affinity of **3g** for thrombin labeled at the active site using fluorescein-FPRCK ( $\lambda_{EX} = 490 \text{ nm}$ ,  $\lambda_{EM} = 525 \text{ nm}$ ). Solid lines represent nonlinear regression fitting using quadratic equation 4 to calculate the  $K_D$  of binding. (C) Dose-response profiles of **3g** against factor Xa and factor XIa with comparison against thrombin. Also shown is the profile for **3g** inhibition of thrombin in the presence of 100 nM antithrombin. Solid lines represent sigmoidal dose-response fits using equation 1 to calculate  $IC_{50}$ ,  $\Delta Y$  and HS.

Fig. S6). Overall, each member of the sulfated coumarin library could be synthesized in less than 6 steps (see Supplementary Information).

This is the first synthesis of a NSGM library based on the coumarin scaffold. The 36 member library contained different locations of the 1 or 2 sulfate group(s), different types of substitutions (-Me, -Ph, -Cl, -Br, etc.), different size of molecules (monomer or dimer), different linker length (n = 3 or 4), and different geometry of constituent units ("head-to-head" or "head-to-tail") (see Fig. 2). Thus, although the library is not large, it presents sufficient possibilities of discovering probes of partial allosterism.

Inhibition and Regulation of Coagulation Factors. The library of sulfated coumarins was first screened against thrombin, as well as related coagulation factors, factor Xa and factor XIa, at a high concentration (250  $\mu$ M) using appropriate chromogenic substrates, as described earlier<sup>29,33,36</sup>. Eleven of the 36 sulfated coumarins displayed reasonable inhibition of thrombin and were selected for further characterization. Figure 3A shows the dose–response profiles of selected sulfated coumarins and a non-sulfated precursor. Supplementary Table S1 lists the half-maximal inhibitory concentration ( $IC_{50}$ ), efficacy of inhibition ( $\Delta$ Y) and Hill slope (HS) for each molecule calculated through non-linear regression analysis (equation 1). In terms of structure–function relationships, the results showed a highly sensitive thrombin inhibition response to the structure of sulfated coumarins. Very few monomeric sulfated coumarins inhibited thrombin (only 2e, 2k and 2p), in contrast to nearly all dimeric sulfated coumarins that displayed good inhibition potencies ( $IC_{50} < 20 \,\mu$ M). Only those monomeric NSGMs

that contained an aromatic group at the 4-position were active, e.g., **2e**, **2k** and **2p**, but not all 4-aryl derivatives were active, e.g., **2d**, **2l**, **2o**, **2w**, **2x** and **2y** (see Supplementary Table S1). One or more halogen atoms were also present on the monomeric scaffold. Each of the active monomers contained one sulfate group, preferably at the 7-position, and removal of this sulfate or introduction of an additional sulfate group (e.g., **2y**, see Fig. 2) led to complete absence of inhibition potential.

The higher reactivity of the 7-OH gave 7–7-linked dimers 3a-3f, which contained sulfation at the 4'-hydroxyphenyl position (see Fig. 2). Although structurally, the dimers cannot be considered as strict analogs of the monomers, the ease of their synthesis led us to study these variants. Each of the dimers studied inhibited thrombin with a higher potency than monomers (Fig. 3A and Supplementary Table S1). Of these, 3a and 3b were most potent ( $IC_{50} \le 1 \mu$ M). Interestingly, 3a and 3b, and not any other dimer, contain 4-phenyl substitution, which mimics the structure–activity relationship observed for monomers. To assess whether an alternative analog would yield similar activity, we synthesized 3g (see Fig. 2). Dimer 3g possesses only one sulfate, opposed to the other six dimers, which have two. Interestingly, 3g inhibited thrombin with an  $IC_{50}$  of 180 nM against thrombin (Supplementary Table S1), the highest potency observed in the group. More importantly, it is selective for thrombin as evidenced by its inhibition potencies against closely related coagulation proteases factors Xa and XIa ( $IC_{50} > 30 \mu$ M, Supplementary Table S1).

Structurally, dimer **3g** shows a couple of similarities with active monomer **2k**. Both contain 4-aryl and *ortho-/para-* dichloro substitution. Considering that **3g** and **2k** are the most potent molecules in their respective groups, it is likely that these substitutions contribute to enhancing potency against thrombin. We speculate that hydrophobic forces play a significant role in targeting thrombin. This is further supported by the observation that **3g**, which contains only one sulfate group, is more potent than the rest of dimers, which contain two sulfate groups. To assess, whether removal of the lone sulfate at the 4'-hydroxyphenyl position in **3g** further enhances potency, we studied non-sulfated precursor **3h** (Fig. 2). Even high concentrations of **3h** did not inhibit thrombin, or any other protease tested (Fig. 3A). This implies that the lone sulfate of **3g** is critical for thrombin inhibition. Yet, this does not conclusively imply that sulfation at the 4'-hydroxyphenyl is the most optimal position. Many analogs of **3g** will need to be studied to establish the structure-activity relationships around this scaffold.

To characterize 3g's thermodynamic affinity for thrombin, we used fluorescein-labeled (*f*FPRCK-) human thrombin and followed its fluorescence as a function of 3g levels, as also performed for other sulfated ligands of coagulation factors<sup>37,38</sup>. As shown in Fig. 3B, a characteristic loss in fluorescence of thrombin was observed, which could be fitted using the quadratic binding equation (equation 4) to obtain a  $K_D$  of  $143 \pm 14$  nM and  $\Delta F_{MAX}$  of ~28%. Thus, the thermodynamic affinity of 3g is in the same range as its inhibition potency. Finally, inhibitor 3g also displays excellent selectivity for thrombin in comparison to that for factor XIa (~150-fold) and factor Xa (~800-fold) (Fig. 3C) highlighting its putative value in studying thrombin allostery and function.

The high potency or selectivity of inhibition noted for **3g** was not the most interesting discovery from this study. It was the variable efficacy ( $\Delta$ Y) of thrombin inhibition. All of sulfated coumarins assayed displayed  $\Delta$ Ys ranging from ~20–70% (Fig. 3A and Supplementary Table S1), indicating that this is a generic property of the sulfated coumarin scaffold. The most potent sulfated coumarin **3g** displayed an efficacy of 47% and a Hill slope of 1.2. Other reasonably potent agents displayed  $\Delta$ Y of 73% (**3a**), 58% (**3b**) and 60% (**3c**). In contrast, sulfated benzofurans and sulfated quinazolinones studied earlier display >80% inhibition<sup>27–29</sup> or no inhibition<sup>33</sup> of thrombin. Likewise, other sulfated molecules described in the literature that inhibit a number of other coagulation factors, e.g., factor Xa<sup>30,39</sup>, factor XIa<sup>33,38</sup>, or plasmin<sup>40,41</sup>, also do not display variable efficacies. Interestingly, the current sulfated coumarins inhibit factors Xa and XIa, which are structurally homologous to thrombin, with efficacies of 80–100% (Fig. 3B and Supplementary Table S1). This implies that sulfated coumarins, in principle, belong to a different class of thrombin inhibitors and present a unique capability of thrombin regulation.

**Mechanism of Thrombin Inhibition by Sulfated Coumarins.** To identify the kinetic mechanism of thrombin inhibition by sulfated coumarins, especially **3g**, we performed Michaelis-Menten kinetic studies using Spectrozyme TH as the substrate. Figure 4A shows the substrate hydrolysis profiles in the presence of **3g**. As the concentration of **3g** increased, the  $V_{MAX}$  decreased from 57.5 to 31.0 mAU/min, whereas the  $K_M$  remained relatively constant (Supplementary Table S2). These results suggest that **3g**, and most probably other sulfated coumarins, non-competitively inhibit thrombin. Further, even at saturating levels of **3g**, the  $V_{MAX}$  did not reduce beyond ~50%, further confirming the partial inhibition characteristic of these inhibitors.

**Site of 3g Binding to Thrombin.** Thrombin possesses two electropositive anion-binding exosites that help regulate its catalytic activity (see also Fig. 1B)<sup>19,20</sup>. Exosite 1 is the site for interaction with fibrinogen, which propagates the clotting signal. It is also the site where hirudin and bivalirudin bind and inhibit thrombin. Exosite 2 is the site where unfractionated heparin (UFH),  $\gamma'$ -fibrinogen, and glycoprotein Ib $\alpha$  bind<sup>19,20,42-45</sup>. To assess whether **3g** interacts with one of these exosites, competition studies were performed. In the presence of fixed concentrations of two competing ligands, a hirudin peptide (HirP, [5F]-Hir-(54–65)-(SO<sub>3</sub><sup>-</sup>)) for exosite 1 and UFH for exosite 2, the catalytic activity of thrombin was measured at varying concentrations of **3g** (Fig. 4B,C). As evident from the profiles, the presence of HirP marginally increased the *IC*<sub>50</sub> of **3g** by 50%, whereas the presence of UFH reduced the potency of **3g** significantly by ~300% (Table 1). Further, comparison of the observed inhibition potency with that calculated on the basis of ideal competition using the Dixon-Webb relationship (see Experimental Procedures) suggests that **3g** competes almost ideally with UFH (Table 1), but not with HirP. Thus, **3g** binds in exosite 2 of thrombin and allosterically inhibits thrombin such that a maximal inhibition of only 50% is produced. The reason why HirP affects **3g** binding to a small extent is most probably coupling between the exosites, as has been documented in the literature<sup>46,47</sup>. Thus, **3g** is the first allosteric, partial inhibitor of thrombin. Although **3g** is a hydrophobic molecule with one sulfate group, it is not too surprising that it binds in the anion-binding exosite 2. A large number of sulfated small and large molecules have been developed to date and



**Figure 4.** Site of 3g binding onto thrombin. (A) Michaelis-Menten kinetics Spectrozyme TH hydrolysis by thrombin in the presence of 3g. The initial rate of hydrolysis at substrate concentrations of 0–250  $\mu$ M was measured at 25 °C and a pH of 7.4, as described in Experimental Procedures. The concentrations of 3g chosen were 0, 25, 187, and 2500 nM. Solid lines represent nonlinear regression fits to the data using the standard Michaelis-Menten kinetics, equation 2. (B) Dose-response profile of 3g inhibition of thrombin in the presence of an exosite 1 ligand, hirudin peptide ([5F]-Hir-(54–65)-(SO<sub>3</sub><sup>--</sup>)) at 25 °C in buffer of pH 7.4. (C) Dose-response profile of 3g inhibition of thrombin in the presence of an exosite 2 ligand, unfractionated heparin. Solid lines represent sigmoidal dose-response fits using equation 1. (D) Comparison of  $IC_{50}$ s of 3g inhibition of recombinant human thrombins. The  $IC_{50}$ s were measured using substrate hydrolysis assays, as shown in Fig. 3. The horizontal line is for comparison of change in  $IC_{50}$  of mutants from that of the wild-type recombinant human thrombin.

	<i>IC</i> <sub>50,арр</sub> (µМ) <sup>ь</sup>	$\Delta Y (\%)^{b}$	HS	IC50,predicted (µM) <sup>c</sup>
[HirP] (nM)				
0	$0.22\pm0.02$	$52\pm 2$	3.3	0.24
25	$0.33\pm0.02$	$58\pm1$	2.4	0.45
187	$0.33\pm0.06$	$59\pm 6$	2.0	0.67
[UFH] (µM)				
0	$0.17\pm0.02$	$56\pm3$	1.3	0.17
11.4	$0.29\pm0.03$	$66\pm5$	1.7	0.29
22.8	$0.58\pm0.03$	$59\pm3$	3.7	0.45

**Table 1.** Thrombin inhibition by 3g in the presence of HirP and UFH<sup>a</sup>. <sup>a</sup>Inhibition was measured at pH 7.4 and 25 °C using chromogenic substrate hydrolysis assay and analyzed using logistic equation 1 to obtain  $IC_{50,app}$ ,  $\Delta$ Y and HS. <sup>b</sup>Errors represent  $\pm$  1 SE obtained from non-linear regression of the inhibition profile. <sup>c</sup>Calculated using Dixon-Webb relationship (equation 3).

found to interact with exosite 2 of thrombin  $^{27,28,36,41}$  or exosite 2-like regions of other homologous coagulation factors  $^{33,38}$ .

To further probe the **3g**-thrombin system, we studied a group of thrombin mutants containing replacement of either Arg or Lys present in exosite 2 to Ala. These site-directed mutants, studied earlier in depth in the Rezaie laboratory<sup>48,49</sup>, encompassed the majority of the electropositive residues present in exosite 2. In comparison to the recombinant wild-type thrombin control, the  $IC_{50}$ s of **3g** inhibition of four mutants (K236A, K235A, R173A and K169A) increased by a small factor (<1.4-fold) (Fig. 4D, see also Supplementary Table S3 showing all parameters). Earlier studies on sulfated benzofurans have shown that disruption of a key interaction through Arg/Lys mutagenesis results in a considerable decrease in potency (~2–10-fold)<sup>24,25</sup> and thus, these small changes suggest that K236, K235, R173 or K169 are most probably not singularly involved in **3g** recognition.

The inhibition potency of **3g** increased for five mutants (R233A, R165A, R126A, R101A, and R93A), of which R93A displayed a dramatic 2.3-fold effect. This is an unusual observation and opposes the expectation of a loss in

potency. Yet, an analysis of thrombin crystal structure shows that a majority of these residues are located adjacent to hydrophobic sub-sites within/near exosite  $2^{50,51}$ . Thus, expansion of the hydrophobic sub-domain through Ala replacement of Arg/Lys may induce better recognition of **3g**'s aliphatic chain and/or aromatic rings resulting in enhancement of potency. This appears to be especially true for the R93A and R101A mutants, and possibly also for others. Earlier work on sulfated low molecular weight lignins has also shown the importance of hydrophobic-ity in recognition of exosite 2 and support the conclusion that **3g** binds in exosite 2 through primarily non-ionic forces<sup>51</sup>.

It is not clear why a specific electropositive amino acid residue was not identified as the primary site of **3g** recognition. It is possible that other Arg/Lys, such as R240, K107, K109, and K110 located within or adjacent to exosite 2, may be involved in interacting with the sulfate group of **3g**. It is also possible that the **3g** interacts with multiple Arg/Lys groups that are near neighbors, e.g., R240, K236, and K235, such that replacement of one does not adversely impact its affinity significantly. This possibility has previously been documented for the thrombin–low molecular weight lignin system and factor XIa–sulfated quinazolinone system, where single mutants showed much weaker changes in activity as compared to triple mutants<sup>33,50</sup>. Overall, this study of site-directed mutants supports the conclusion that **3g** utilizes hydrophobic forces in binding and that one or more Arg/Lys residue within or adjacent to exosite 2 may be the target of its sulfate group.

The study of recombinant thrombins also enables further confirmation of the partial inhibition phenomenon. Supplementary Table S3 lists the efficacies of each thrombin studied. The results show **3g** induces maximal inhibition efficacies in the range of 28 to 64%, which are comparable to that measured for sulfated coumarins inhibiting plasma thrombin. The retention of the partial inhibition phenomenon by recombinant thrombins shows that changes in the electrostatics of exosite 2 does not impact the intrinsic property of sulfated coumarins, especially **3g**.

**3g Induces Conformational Allostery.** In principle, allosterism may arise from conformational changes or dynamic changes introduced by the allosteric ligand. Conformational changes imply structural changes in the target macromolecule<sup>52,53</sup>, whereas dynamic changes imply alteration in the flexibility of the target macromolecule<sup>54–56</sup>. It is also possible that allostery arises from a combination of both types of changes. Considering that thrombin displays an ensemble of ground states (Fig. 1B)<sup>11,21,57</sup>, it is important to understand whether **3g** introduces conformational or dynamic allostery.

To elucidate the nature of allostery, two orthogonal experiments were performed. First, fluorescence-quenching studies were performed on thrombin complexes with **3g** and a previously studied sulfated benzofuran trimer<sup>28</sup> (**BT**), which displays inhibition efficacy >80%. Iodide anion is a well-established agent that is known to quench fluorescence through collisional interactions<sup>58</sup>. We reasoned that if **3g** induces less conformational changes in the protein in comparison to **BT**, then access of an active site fluorophore to the iodide anion should be different. Thus, quenching of fluoresceinylated thrombin, i.e., *f* FPRCK-thrombin, by iodide was studied in the presence and absence of **3g** and **BT**, respectively (Fig. 5A) and analyzed using Stern-Volmer relationships (Fig. 5B). The results revealed that the calculated slope of quenching for thrombin alone was  $2.37 \pm 0.14 M^{-1}$ , which decreased to  $1.19 \pm 0.06 M^{-1}$  in the presence of **3g** (90% saturation) and to  $0.69 \pm 0.02 M^{-1}$  in the presence of **BT** (90% saturation). Thus, **3g** reduces iodide quenching of *f*FPRCK-thrombin by ~50%, while **BT** reduces by ~71%.

Although the above results indicate that **3g**, but not **BT**, induces partial conformational change in thrombin, a remote possibility of differential quenching by iodide anion is physical shielding by **3g**, but not **BT**. Both **3g** and **BT** bind in exosite  $2^{28}$ , which is too far away (~20 Å) from the site of the fluorescein label (thrombin's S4 pocket). Further, this study shows that **3g** binding affinity correlates well with its  $IC_{50}$ . If any part of **3g** structure was located at the S4 site, the affinity should have been lower. Thus, the results suggest that the observed efficacy ( $\Delta$ Y) of inhibition correlates with the ability of iodide anion to access to the active site fluorescein label, which is modulated by the allosteric inhibitor. Alternatively, **3g** induces a much smaller change in the orthosteric site in comparison to that of **BT**, which suggests a structural basis for its allosterism.

To further probe whether **3g** indeed induces changes in the orthosteric site, we studied the kinetics of the thrombin-antithrombin reaction in the presence of **3g** using a discontinuous spectrophotometric assay, as described earlier<sup>59,60</sup>. Figure 6A shows time profiles of thrombin inactivation at varying 3g levels under pseudo-first order conditions, which were analyzed to derive the observed rate constant ( $k_{OBS}$ ). The intrinsic rate constant of antithrombin inhibition of thrombin, i.e.,  $k_{IND}$  which is proportional to the concentration of antithrombin, was calculated from  $k_{OBS}$  using equation 6. A plot of  $k_{INT}$  versus percent saturation of thrombin with 3g (Fig. 6) shows an expected linear relationship that displays an intercept of  $2476 \pm 228 \, \text{M}^{-1} \text{s}^{-1}$  corresponding to the second order rate constant of antithrombin inhibition of thrombin alone in the absence of 3g. More importantly, the  $k_{INT}$  at 100% saturation of thrombin, i.e., for thrombin–3g complex, was calculated to be  $821 \pm 198 \text{ M}^{-1} \text{s}^{-1}$ . When similar experiments were performed for antithrombin-factor Xa system, **3g** did not induce any change in the second-order rate constant of inhibition (Supplementary Fig. S7). This demonstrates that the thrombin-3g complex retains significant proteolytic activity, in contrast to the nearly zero activity expected for a fully inhibited system. Thus, this suggests that **3g** induces an intermediate structural change in the active site of thrombin, which depresses the intrinsic reactivity of thrombin with antithrombin. If  $k_{INT}$  in the absence of **3g** is equated with 100% proteolytic activity, then these results imply that thrombin-**3g** complex is  $33 \pm 12\%$  active, which corresponds reasonably well to the efficacy of **3g** inhibition of thrombin ( $\Delta Y \sim 49\%$ ). Therefore, 3g inhibits thrombin by inducing a partial structural change in its active site.

**Significance.** This work presents the first group of small molecules that induce partial allosteric inhibition in a monomeric protease. Mechanistically, this is very interesting and shows that it is possible to regulate monomeric proteases in a manner similar to multimeric proteins and receptors. Our work also shows that partial inhibition arises from a structural change in the catalytic site, just as partial agonism or antagonism is also associated with



Figure 5. Conformational allostery induced by 3g in thrombin. (A) Change in *f*FPRCK-thrombin fluorescence with increasing concentrations of NaI in the presence of 1  $\mu$ M 3g and 2.5  $\mu$ M BT in pH 7.4 buffer at 25 °C. Excitation and emission wavelengths were 490 nm and 525 nm, respectively. (B) Stern-Volmer analysis of the data presented above. Solid line represents linear fit to the data to calculate the slope, or sensitivity of the active site fluorophore to molecular collisions with iodide, at pH 7.4 and 25 °C.

structural change at the distal site<sup>2,17</sup>. Thermodynamically, our work shows that it is not necessary for inhibition of monomeric proteases to exhibit a two-state equilibrium between native and fully inhibited states. As shown for thrombin, an intermediate state may exhibit sufficient stability to be exclusively populated when saturated by an appropriate ligand. The fact that such a phenomenon, i.e., partial allosterism of soluble, monomeric proteases, has not been documented in the literature highlights the challenge and value of this work.

Sulfated coumarins, especially **3g**, are able to bring about a limited conformational change in the active site of the thrombin, so as to still allow room for binding and cleavage of small substrates. Whether this phenomenon holds true for macromolecular substrates of thrombin<sup>19,20,61</sup> such as fibrinogen, factor V, factor VIII, factor XI, factor XIII and protein C remains to be determined. If allosteric partial inhibition translates to one or more macromolecular substrates, it will offer significant advantages over other thrombin inhibitors that display 100% inhibition, e.g., dabigatran and argatroban. A simplistic prediction would be that partial allosteric inhibition of thrombin will enable a homeostatic state. For example, it can be expected to only depress fibrinogen cleavage, and not completely inhibit it, such that a balance between procoagulant and anticoagulant tendencies is achieved resulting in homeostasis<sup>25</sup>. Such a natural state is not achieved with orthosteric inhibitiors used in the clinic today resulting in considerable bleeding<sup>23,24,62</sup>. Thus, the concept of partial allosteric inhibition in general, and specifically for thrombin, may have major implications for therapy.

Our work adds further support to conclusions derived in the literature that thrombin is a highly plastic enzyme<sup>11,21,57</sup>. Whether **3g** selects out one of the conformations from the ensemble present in its native state or induces a new form remains to be determined. Advanced stopped-flow kinetic studies, such as performed for thrombin – hirudin system<sup>63</sup>, may be able to clarify between the two possibilities. However, the discovery of partial allosterism for thrombin adds to the level of plasticity afforded by this key enzyme of the coagulation cascade. In fact, thrombin appears to exhibit properties well known for multimeric receptors.

In addition to the partial allosteric features, our work presents **3g** as the most potent small molecule exosite 2 inhibitor of thrombin discovered to date. The sulfated benzofurans developed earlier display potencies in the range of 0.7–200  $\mu$ M<sup>27–29</sup>. Likewise, suramin, a sulfonated aromatic molecule, inhibits thrombin with 20–40  $\mu$ M IC<sub>50</sub><sup>64</sup>. Heparin hexasaccharide is not an inhibitor of thrombin, but binds with an affinity of ~8  $\mu$ M<sup>65</sup>. The only molecules that target exosite 2 and inhibit thrombin with higher potency are the sulfated low molecular weight lignins (10–150 nM IC<sub>50</sub>)<sup>30,36,39</sup>, however, these are heterogeneous, oligomeric mixtures. Thus, **3g** could be classified as a good scaffold for the discovery of better partial allosteric regulators of hemostasis.

Overall, this initial discovery is extremely promising from the perspective of pursuing partial allosterism as a novel mechanism for regulators of monomeric proteases. It is possible that partial allosterism of monomeric



**Figure 6.** Structural changes induced in the active site of thrombin by 3g. (A) Residual thrombin activity as a function of time following incubation with excess antithrombin in the presence of fixed concentrations of **3g** (0–675 nM) in pH 7.2 buffer at 25 °C. Solid lines represent exponential fits to the data using equation 6 to calculate the pseudo first order rate constant  $k_{OBS}$ . (B) Dependence of intrinsic second order rate constant of thrombin–antithrombin reaction ( $k_{INT}$ ), calculated from  $k_{OBS}$  (above) using equation 7, as a function of the percent saturation of thrombin at different levels of **3g** (i.e., [thrombin–**3g**]/[thrombin]). Solid line represents linear fit to the data to obtain the  $k_{INT}$  for thrombin–**3g** complex at pH 7.2 and 25 °C.

proteases is a more general phenomenon and further effort will help identify 'regulators', rather than 'inhibitors', that lead to homeostasis.

#### **Experimental Methods**

**Chemicals, Proteins, Substrates and Reagents.** Anhydrous and chromatography solvents were from Sigma Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA). Acetone- $d_6$  and DMSO- $d_6$  for NMR were from Sigma Aldrich (Milwaukee, WI) or Acros Organics (Morris Plains, NJ). Chemical reagents including BBr<sub>3</sub>, SO<sub>3</sub> • N(CH<sub>3</sub>)<sub>3</sub>, Cs<sub>2</sub>CO<sub>3</sub>, CuSO<sub>4</sub> • 5H<sub>2</sub>O, sodium ascorbate, triethylamine (TEA), propargyl bromide, 1-bromo-3-chloropropane, 1-bromo-4-chlorobutane, sodium azide, and TBTA were from Sigma Aldrich (Milwaukee, WI), Fisher Scientific (Pittsburgh, PA), or Acros Organics (Morris Plains, NJ) and used as purchased. Coumarins were from Indofine Chemical Company Inc. (Hillsborough, NJ). All other chemicals were analytical reagent grade or higher and obtained from Sigma Aldrich (Milwaukee, WI) or Fisher Scientific (Pittsburgh, PA).

Human plasma proteases including thrombin, fluorescein-labeled (*f*FPRCK-)thrombin, antithrombin, factor Xa and factor XIa were from Haematologic Technologies (Essex Junction, VT). Recombinant thrombins were gifts from the Rezaie lab (St. Louis University). Spectrozyme TH (*H*-D-cyclohexylalanyl-Ala-Arg-*p*-nitroanilide) and Spectrozyme FXa (methoxycarbonyl-D-cyclohexylglycyl-Gly-Arg-*p*-nitroanilide) were from Sekisui Diagnostics (Lexington, MA). S-2366 (L-pyroGlu-Pro-Arg-*p*-nitroaniline • HCl) was from Diapharma (West Chester, OH). Bovine unfractionated heparin was from Sigma Aldrich and hirudin peptide (HirP, [5F]-Hir-(54–65)-(SO<sub>3</sub><sup>-</sup>)) was from Anaspec (Fremont, CA).

**Enzyme Inhibition Studies.** Chromogenic substrate hydrolysis assay was used to measure potency of inhibition, as previously reported<sup>28,29</sup>. The assay was performed using Flexstation III (Molecular Devices, Sunnyvale, CA) by monitoring substrate hydrolysis at 405 nm. For thrombin and its mutants, 180  $\mu$ L of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% (polyethylene glycol) PEG 8000, pH 7.4) was added to each well followed by 5  $\mu$ L of 240 nM thrombin and 10  $\mu$ L of sulfated coumarin in DMSO to give 0.002 to 250  $\mu$ M final concentration (or 10  $\mu$ L of DMSO alone). After incubation for 10 min at 25 °C, 5  $\mu$ L of 2 mM Spectrozyme TH was added to each well simultaneously and allowed to react for 60 seconds at 25 °C while simultaneously monitoring the reaction to obtain the rate of increase in A<sub>405</sub>. Identical experimental conditions were used for reactions in the presence of antithrombin, except for 100 nM of antithrombin added prior to the addition of the substrate.

For factor XIa inhibition studies, 85  $\mu$ L of buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% PEG 8000, 0.02% Tween 80, pH 7.4) was added to each well, followed by 7  $\mu$ L of 15.3 nM enzyme and 3  $\mu$ L of sulfated coumarin (3.75–500  $\mu$ M final concentration) and incubated for 10 min at 37 °C. After the incubation period, 5  $\mu$ L of 6.9 mM S-2366 was added to each well simultaneously and allowed to react for 300 sec at 37 °C. For factor Xa assay, 180  $\mu$ L of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% PEG 8000, 0.02% Tween 80, pH 7.4) was added to each well followed by 5  $\mu$ L of 43.5 nM enzyme, 10  $\mu$ L of sulfated coumarin (0.002–250  $\mu$ M final concentration). After a 10 min incubation, 5  $\mu$ L of 5 mM Spectrozyme FXa was added to each well simultaneously and allowed to react for 300 seconds at 37 °C. The slopes generated from each experiment were used to calculate the fractional residual activity (*Y*) at each concentration of the inhibitor, and analyzed using logistic equation 1, in which *Y*<sub>M</sub> is the maximum efficacy, *Y*<sub>0</sub> is minimum efficacy and HS is the Hill slope.

$$Y = Y_{\rm o} + \frac{Y_{\rm M} - Y_{\rm o}}{1 + 10^{(\log [{\rm Inhibitor}]_{\rm o} - \log {\rm IC}_{50}) \times {\rm HS}}}$$
(1)

**Michaelis-Menten Kinetic Studies.** Four concentrations (0, 25, 187, and 2500 nM) of **3g** were studied in triplicate where **3g** was incubated with thrombin for 10 min in buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% PEG 8000, pH 7.4) at 25 °C. Spectrozyme TH at various concentrations (0–250  $\mu$ M) was added at each of the four **3g** concentrations and the initial rate of hydrolysis was recorded from the increase in A<sub>405</sub> as a function of time. This slope was fitted to the standard Michaelis-Menten equation to derive  $V_{MAX}$  and  $K_M$  of the reaction at each of the **3g** concentrations.

. . .

$$v = \frac{V_{MAX}[S]}{K_M + [S]} \tag{2}$$

**Competition Studies with Exosites 1 and 2 Ligands.** Thrombin inhibition by **3g** was examined in the presence of either HirP (exosite 1 ligand) or UFH (exosite 2 ligand). **3g** was prepared in DMSO (0.010–50  $\mu$ M) and thrombin (4–8 nM) were incubated at 25 °C with HirP (0–187 nM) or UFH (0–22.8  $\mu$ M) in buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% PEG 8000, pH 7.4). After 10 min, thrombin activity was measured using Spectrozyme TH hydrolysis assay, as described above. The slopes obtained (in triplicate) were fitted using equation 1 to calculate  $IC_{50,app}$ ,  $\Delta Y$ , and *HS*. The  $IC_{50,app}$  at each concentration of the competitor was also calculated using the Dixon-Webb relationship (equation 3) from the known affinities ( $K_{comp}$ ) of the competitor.

$$IC_{50,app} = (IC_{50,obs}) \left( 1 + \frac{[comp]}{K_{comp}} \right)$$
(3)

**Thermodynamic Affinity Studies.** Affinity studies were performed in triplicate and conducted using quartz cuvettes. 180 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% PEG 8000, pH 7.4) and 20 µL of 2 µM fluorescein-labeled (*f*FPRCK-) thrombin were added to the cuvette followed by titration with 1 µL additions of **3g**. Fluorescence intensities were monitored by excitation at 490 nm and emission at 525 nm using slit widths of 0.5 mm. The  $K_D$  of **3g**-thrombin complex was calculated using the quadratic binding equation (equation 4) in which  $\Delta F$  is the change in fluorescence from the formation of the thrombin-ligand complex with each addition of **3g**.  $F_0$  is the initial fluorescence and  $\Delta F_{MAX}$  represents the maximum observed change in fluorescence due to thrombin saturation ([Th]<sub>0</sub>). The binding was assumed to possess a stoichiometry of 1:1.

$$\frac{\Delta F}{F_{o}} = \frac{\Delta F_{MAX}}{F_{o}} \left\{ \frac{\left[ \left[ \text{Th} \right]_{o} + \left[ 3\mathbf{g} \right]_{o} + K_{D} - \sqrt{\left( \left[ \text{Th} \right]_{o} + \left[ 3\mathbf{g} \right]_{o} + K_{D} \right)^{2} - 4\left[ \text{Th} \right]_{o} \left[ 3\mathbf{g} \right]_{o}} \right]}{\left( 2\left[ \text{Th} \right]_{o} \right)} \right\}$$
(4)

**Fluorescence Quenching Studies.** The quenching studies performed were done using quartz cuvettes, as described previously<sup>36,58</sup>. 180 µL of buffer (20 mM Tris-HCl, 100 mM NaCl, 2.5 mM CaCl<sub>2</sub>, 0.1% PEG 8000, pH 7.4) and 20 µL of 2 µM fluorescein-labeled (*f*FPRCK-) human thrombin were added to the cuvette; fluorescent intensity readings were taken at the  $\lambda_{EX}$  of 490 nm and  $\lambda_{EM}$  of 525 nM at 25 °C. A solution of 10 M NaI was made using buffer as the solvent. For the readings where inhibitor was absent, 1 µL increments of 10 M NaI was added directly to the cuvette after initial readings of the buffer-thrombin solution. NaI was added six times, while recording changes in fluorescent intensity each time, giving a concentration range of 0–3.0 M in the cuvette. For the readings where inhibitor was present, after the initial buffer-thrombin read, 1 µL of 80 µM inhibitor solution was added to the cuvette and mixed. An intensity reading was taken and then the addition of 1 µL increments of 10 M NaI was again performed six times, taking reads between each addition. The experiments were performed in triplicate and averaged. Initial fluorescence (F<sub>0</sub>) was the intensity reading from either the buffer-thrombin solution in the absence of **3g** or following addition of 1 µL of **3g**. Linear regression was performed using Stern-Volmer relationship (equation 5), in which *F* is the intensity with quencher, [Q] is the concentration of quencher, and  $K_{SV}$  is the dynamic quenching constant given by the slope.

$$\frac{F_0}{F} = 1 + K_{SV}[Q]$$
(5)

Antithrombin Inactivation of Thrombin or Factor Xa in the Presence of Sulfated Coumarin. The effect of 3g on the reaction of thrombin (or factor Xa) with antithrombin was studied under pseudo-first order conditions such that  $[AT]_0 \gg [T]_0$ . A fixed concentration of 6 nM plasma  $\alpha$ -thrombin in 20 mM Tris-HCl buffer, pH 7.2, containing 100 mM NaCl, 2.5 mM CaCl, and 0.1% PEG 8000 at 25 °C was incubated for 128 min with final concentrations of 0, 75, 225, or 675 nM of **3g** following which a fixed concentration of 100 nM of antithrombin was added and the reaction allowed to proceed. Similarly, 5 nM of plasma factor Xa in 20 mM Tris-HCl buffer, pH 7.2, containing 100 mM NaCl, 2.5 mM CaCl<sub>2</sub> and 0.1% PEG 8000 at 25 °C was incubated for 210 min with final concentrations of 0 or 220 nM of 3g following addition of a fixed concentration of 100 nM of antithrombin was added and the reaction allowed to proceed. At a defined time point, a small aliquot of Spectrozyme TH was added to a final concentration of  $50 \,\mu\text{M}$  for thrombin and Spectrozyme Xa a final concentration of  $150 \,\mu\text{M}$  for factor Xa. The initial rate of hydrolysis of the Spectrozymes were monitored from the linear increase in  $A_{405}$ . The fractional residual enzyme activity at each time point was calculated from the slope, i.e., thrombin activity, measured at the start of the experiment and fitted by the standard exponential decay equation 6 to calculate the observed pseudo-first order rate constant, k<sub>OBS</sub>, at each concentration of 3g. The intrinsic second-order rate constant of antithrombin inhibition of thrombin  $(k_{\text{INT}})$  was calculated using equation 7 and plotted against the concentration of thrombin–3g complex, obtained from quadratic equation 8, to derive the  $k_{\rm INT}$  of antithrombin inhibition of thrombin-3g complex.

$$[A] = [A]_0 e^{-k_{OBS}t} \tag{6}$$

$$k_{OBS} = k_{INT} [AT]_0 \tag{7}$$

$$[TH - 3g] = \frac{\left([TH]_0 + [3g] + K_D\right) \pm \sqrt{\left([TH]_0 + [3g] + K_D\right)^2 - 4\left([TH]_0 [3g]\right)}}{2}$$
(8)

#### References

- Merdanovic, M., Monig, T., Ehrmann, M. & Kaiser, M. Diversity of allosteric regulation in proteases. ACS Chem. Biol. 8, 19–26 (2013).
- 2. Nussinov, R., Tsai, C. J. & Csermely, P. Allo-network drugs: harnessing allostery in cellular networks. *Trends Pharmacol. Sci.* 32, 686–693 (2011).
- Gentry, P. R., Sexton, P. M. & Christopoulos, A. Novel allosteric modulators of G protein-coupled receptors. J. Biol. Chem. 290, 19478–19488 (2015).
- Bridges, T. M. & Lindsley, C. W. G-protein-coupled receptors: From classical modes of modulation to allosteric mechanisms. ACS Chem. Biol. 3, 530–541 (2008).
- Christopoulos, A. Allosteric binding sites on cell-surface receptors: Novel targets for drug discovery. Nat. Rev. Drug Discov. 1, 198–210 (2002).
- Arnaout, M. A., Mahalingam, B. & Xiong, J. P. Integrin structure, allostery, and bidirectional signaling. Annu. Rev. Cell Develop. Biol. 21, 381–410 (2005).
- Lavoie, H., Li, J. J., Thevakumaran, N., Therrien, M. & Sicheri, F. Dimerization-induced allostery in protein kinase regulation. *Trends Biochem. Sci.* 39, 475–486 (2014).
- Fang, Z. Z., Grutter, C. & Rauh, D. Strategies for the selective regulation of kinases with allosteric modulators: Exploiting exclusive structural features. ACS Chem. Biol. 8, 58–70 (2013).
- 9. Shen, A. Allosteric regulation of protease activity by small molecules. Mol. Biosyst. 6, 1431-1443 (2010).
- 10. Gohara, D. W. & Di Cera, E. Allostery in trypsin-like proteases suggests new therapeutic strategies. *Trends Biotechnol.* **29**, 577–585 (2011).
- Lechtenberg, B. C., Freund, S. M. V. & Huntington, J. A. An ensemble view of thrombin allostery. *Biol. Chem.* 393, 889–898 (2012).
   Ascenzi, P. *et al.* Allosteric modulation of monomeric proteins. *Biochem. Mol. Biol. Edu.* 33, 169–176 (2005).
- 13. Kraut, J. Serine proteases: structure and mechanism of catalysis. Annu. Rev. Biochem. 46, 331-358 (1977).
- 14. Hauske, P., Ottmann, C., Meltzer, M., Ehrmann, M. & Kaiser, M. Allosteric regulation of proteases. *ChemBiochem* 9, 2920–2928 (2008).
- Nussinov, R. & Tsai, C. J. The different ways through which specificity works in orthosteric and allosteric drugs. Curr. Pharm. Des. 18, 1311–1316 (2012).
- Lewis, J. A., Lebois, E. P. & Lindsley, C. W. Allosteric modulation of kinases and GPCRs: design principles and structural diversity. *Curr. Opin. Chem. Biol.* 12, 369–280 (2008).
- Hoyer, D. & Boddeke, H. W. Partial agonists, full agonists, antagonists: dilemmas of definition. *Trends Pharmacolog. Sci.* 14, 270–275 (1993).
- Nakagawa, A. et al. Identification of a small molecule that increases hemoglobin oxygen affinity and reduces SS erythrocyte sickling. ACS Chem. Biol. 9, 2318–2325 (2014).
- 19. Huntington, J. A. Molecular recognition mechanisms of thrombin. J. Thromb. Haemost. 3, 1861–1872 (2005).
- 20. Di Cera, E., Dang, Q. D. & Ayala, Y. M. Molecular mechanisms of thrombin function. Cell. Mol. Life Sci. 53, 701-730 (1997).
- 21. Huntington, J. A. Thrombin plasticity. Biochim. Biophys. Acta 1824, 246-252 (2012).
- 22. Papaconstantinou, M. E., Gandhi, P. S., Chen, Z., Bah, A. & Di Cera, E. Na(+) binding to meizothrombin desF1. *Cell. Mol. Life Sci.* **65**, 3688–3697 (2008).
- Baber, U., Mastoris, I. & Mehran, R. Balancing ischaemia and bleeding risks with novel oral anticoagulants. Nat. Rev. Cardiol. 11, 693–703 (2014).
- 24. Miesbach, W. & Seifried, E. New direct oral anticoagulants-current therapeutic options and treatment recommendations for bleeding complications. *Thromb. Haemost.* **108**, 625–632 (2012).

- 25. Mehta, A. Y. *et al.* Allosterism-based simultaneous, dual anticoagulant and antiplatelet action allosteric inhibitor targeting the glycoprotein Ibalpha and heparin-binding site of thrombin. *J. Thromb. Haemost.* In press, doi: 10.1111/jth.13254 (2016).
- Verghese, J. et al. First steps in the direction of synthetic, allosteric, direct inhibitors of thrombin and factor Xa. Bioorg. Med. Chem. Lett. 19, 4126–4129 (2009).
- 27. Abdel Aziz, M. H. et al. Designing allosteric regulators of thrombin. Monosulfated benzofuran dimers selectively interact with Arg173 of exosite 2 to induce inhibition. J. Med. Chem. 55, 6888–6897 (2012).
- Sidhu, P. S. et al. Designing allosteric regulators of thrombin. Exosite 2 features multiple subsites that can be targeted by sulfated small molecules for inducing inhibition. J. Med. Chem. 56, 5059–5070 (2013).
- 29. Sidhu, P. S. et al. Rational design of potent, small, synthetic allosteric inhibitors of thrombin. J. Med. Chem. 54, 5522-5531 (2011).
- Henry, B. L., Thakkar, J. N., Liang, A. & Desai, U. R. Sulfated, low molecular weight lignins inhibit a select group of heparin-binding serine proteases. *Biochem. Biophys. Res. Commun.* 417, 382–386 (2012).
- Vrakas, D., Tsantili-Kakoulidou, A. & Hadjipavlou-Litina, D. Exploring the consistency of logP estimation for substituted coumarins. QSAR Combinat. Sci. 22, 622–629 (2003).
- Borges, F., Roleira, F., Milhazes, N., Santana, L. & Uriarte, E. Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr. Med. Chem. 12, 887–916 (2005).
- Karuturi, R., Al-Horani, R. A., Mehta, S. C., Gailani, D. & Desai, U. R. Discovery of allosteric modulators of factor XIa by targeting hydrophobic domains adjacent to its heparin-binding site. J. Med. Chem. 56, 2415–2428 (2013).
- Raghuraman, A., Riaz, M., Hindle, M. & Desai, U. R. Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds. *Tetrahedron Lett.* 48, 6754–6758 (2007).
- 35. Al-Horani, R. A. & Desai, U. R. Chemical sulfation of small molecules advances and challenges. Tetrahedron 66, 2907-2918 (2010).
- Mehta, A. Y. et al. Targeting the GPIbalpha binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects. J. Med. Chem. 57, 3030–3039 (2014).
- 37. Desai, B. J. et al. Interaction of thrombin with sucrose octasulfate. Biochemistry 50, 6973-6982 (2011).
- Al-Horani, R. A., Ponnusamy, P., Mehta, A. Y., Gailani, D. & Desai, U. R. Sulfated pentagalloylglucoside is a potent, allosteric, and selective inhibitor of factor XIa. J. Med. Chem. 56, 867–878 (2013).
- Henry, B. L., Monien, B. H., Bock, P. E. & Desai, U. R. A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids. J. Biol. Chem. 282, 31891–31899 (2007).
- 40. Al-Horani, R. A., Karuturi, R., White, D. T. & Desai, U. R. Plasmin regulation through allosteric, sulfated, small molecules. *Molecules* 20, 608–624 (2015).
- Henry, B. L., Abdel Aziz, M., Zhou, Q. & Desai, U. R. Sulfated, low-molecular-weight lignins are potent inhibitors of plasmin, in addition to thrombin and factor Xa: Novel opportunity for controlling complex pathologies. *Thromb. Haemost.* 103, 507–515 (2010).
- 42. Lechtenberg, B. C., Freund, S. M. & Huntington, J. A. GpIbalpha interacts exclusively with exosite II of thrombin. J. Mol. Biol. 426, 881-893 (2014).
- Ye, J., Rezaie, A. R. & Esmon, C. T. Glycosaminoglycan contributions to both protein-C activation and thrombin inhibition involve a common arginine rich site in thrombin that includes residues arginine-93, arginine-97, and arginine-101. J. Biol. Chem. 269, 17965–17970 (1992).
- 44. Carter, W. J., Cama, E. & Huntington, J. A. Crystal structure of thrombin bound to heparin. J. Biol. Chem. 280, 2745-2749 (2005).
- 45. Lovely, R. S., Moaddel, M. & Farrell, D. H. Fibrinogen gamma' chain binds thrombin exosite II. J. Thromb. Haemost. 1, 124–131 (2003).
- 46. Fredenburgh, J. C., Stafford, A. R. & Weitz, J. I. Evidence for allosteric linkage between exosites 1 and 2 of thrombin. *J. Biol. Chem.* **272**, 25493–25499 (1997).
- Verhamme, I. M., Olson, S. T., Tollefsen, D. M. & Bock, P. E. Binding of exosite ligands to human thrombin. Re-evaluation of allosteric linkage between thrombin exosites I and II. J. Biol. Chem. 277, 6788–6798 (2002).
- Yang, L. & Rezaie, A. R. Calcium-binding sites of the thrombin-thrombomodulin-protein C complex: possible implications for the effect of platelet factor 4 on the activation of vitamin K-dependent coagulation factors. *Thromb. Haemost.* 97, 899–906 (2007).
- 49. He, X., Ye, J., Esmon, C. T. & Rezaie, A. R. Influence of arginines 93, 97, and 101 of thrombin to its functional specificity. *Biochemistry* 36, 8969–8976 (1997).
- Aziz, M. H. A., Mosier, P. D. & Desai, U. R. Identification of the site of binding of sulfated, low molecular weight lignins on thrombin. Biochem. Biophys. Res. Commun. 413, 348–352 (2011).
- 51. Mehta, A. Y. & Desai, U. R. Substantial non-electrostatic forces are needed to induce allosteric disruption of thrombin's active site through exosite 2. *Biochem. Biophys. Res. Commun.* **452**, 813–816 (2014).
- 52. Motlagh, H. N., Wrabl, J. O., Li, J. & Hilser, V. J. The ensemble nature of allostery. *Nature* 508, 331–339 (2014).
- 53. Monod, J., Changeux, J. P. & Jacob, F. Allosteric proteins and cellular control systems. J. Mol. Biol. 6, 306–329 (1963).
- 54. Ma, B., Tsai, C. J., Haliloglu, T. & Nussinov, R. Dynamic allostery: linkers are not merely flexible. Structure 19, 907–917 (2011).
- Tsai, C. J., del Sol, A. & Nussinov, R. Allostery: absence of a change in shape does not imply that allostery is not at play. J. Mol. Biol. 378, 1–11 (2008).
- Cooper, A. & Dryden, D. T. F. Allostery without conformational change a plausible model. *Eur. Biophys. J. Biophys.* 11, 103–109 (1984).
- Malovichko, M. V., Sabo, T. M. & Maurer, M. C. Ligand binding to anion-binding exosites regulates conformational properties of thrombin. J. Biol. Chem. 288, 8667–8678 (2013).
- Moller, M. & Denicola, A. Protein tryptophan accessibility studied by fluorescence quenching. *Biochem. Mol. Biol. Edu.* 30, 175–178 (2002).
- Boothello, R. S. et al. Chemoenzymatically prepared heparan sulfate containing rare 2-O-sulfonated glucuronic acid residues. ACS Chem. Biol. 10, 1485–1494 (2015).
- Olson, S. T., Bjork, I. & Shore, J. D. Kinetic characterization of heparin-catalyzed and uncatalyzed inhibition of blood-coagulation proteinases by antithrombin. *Methods Enzymol.* 222, 525–559 (1993).
- Siller-Matula, J. M., Schwameis, M., Blann, A., Mannhalter, C. & Jilma, B. Thrombin as a multi-functional enzyme. Focus on *in vitro* and *in vivo* effects. *Thromb. Haemost.* 106, 1020–1033 (2011).
- 62. Bane, C. E. & Gailani, D. Factor XI as a target for antithrombotic therapy. Drug Discov. Today 19, 1454-1458 (2014).
- Jackman, M. P., Parry, M. A., Hofsteenge, J. & Stone, S. R. Intrinsic fluorescence changes and rapid kinetics of the reaction of thrombin with hirudin. J. Biol. Chem. 267, 15375–15383 (1992).
- 64. Monteiro, R. Q., Campana, P. T., Melo, P. A. & Bianconi, M. L. Suramin interaction with human alpha-thrombin: inhibitory effects and binding studies. *Int. J. Biochem. Cell Biol.* **36**, 2077–2085 (2004).
- 65. Olson, S. T., Halvorson, H. R. & Bjork, I. Quantitative characterization of the thrombin-heparin interaction. Discrimination between specific and nonspecific binding models. J. Biol. Chem. 266, 6342–6352 (1991).

#### Acknowledgements

We thank Professor Rezaie (St. Louis University) for the gift of recombinant thrombins. This work was supported by grants HL090586, HL107152, and HL128639 from the National Institutes of Health to URD.

#### **Author Contributions**

S.V. performed sulfated coumarin library synthesis, biochemical experiments and prepared the initial draft of manuscript; A.Y.M performed MS analysis and affinity studies; D.A. and R.A.A.H performed inhibition studies; U.R.D. supervised the study and finalized the paper.

#### Additional Information

Supplementary information accompanies this paper at http://www.nature.com/srep

**Competing financial interests:** The authors declare that an invention disclosure on sulfated coumarins as regulators of thrombin has been filed with Virginia Commonwealth University. There are no other competing financial interests.

**How to cite this article**: Verespy III, S. *et al.* Allosteric Partial Inhibition of Monomeric Proteases. Sulfated Coumarins Induce Regulation, not just Inhibition, of Thrombin. *Sci. Rep.* **6**, 24043; doi: 10.1038/srep24043 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/